ライフサイエンスコーパス: ddA

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 3'-azido-2',3'-ddN including 3'-azido-2',3'-ddA (AZddA), 3'-azido-2',3'-ddC (AZddC), 3'-azido-2',3'-

2 ably, the higher toxicities of d4T, ddC, and ddA arose from their 13-36-fold tighter binding relative

3 cleoside triphosphates, ddT triphosphate and ddA triphosphate, did not inhibit the integrase at 800 a

4 tudy, FAAddP underwent reduction to 2'-F-ara-ddA followed by deamination to 2'-F-ara-ddI.

5 The conversion of FAAddP to 2'-F-ara-ddA was mediated by microsomal P-450 NADPH reductase sys

6 paws was acutely reversed by chelerythrine, ddA, TMB-8, or Quin-2 but not by NMLA.

7 uorocytidine (FddC), 2',3'-dideoxyadenosine (ddA), and 2'-beta-fluoro-2',3'-dideoxyadenosine (FddA)]

8 yl cyclase inhibitor 2',5'-dideoxyadenosine (ddA), or the calcium chelators 3,4,5-trimethoxybenzoic a

9 ine, dideoxyinosine (ddI), dideoxyadenosine (ddA), didehydrothymidine (d4T), or phosphonoformic acid

10 denylate cyclase inhibitor dideoxyadenosine (ddA) abolished the butyrate-induced: (i) accumulation of

11 ofuryl)-adenine] and 2',5'-dideoxyadenosine (ddAd) are effective and potent AC inhibitors in HEK293 c

12 of 2'-beta-fluoro-2',3'-dideoxyadenosine (F-ddA, lodenosine), a new anti-HIV drug, in human lymphocy

13 2, 1.7x) to much slower (NHEt, 5000x) than F-ddA.

14 ls from HIV-infected patients treated with F-ddA at 3.2 mg/kg twice daily for 22 days shows F-ddATP l

15 Reaction of chloroacetaldehyde with F-ddA triphosphate in extracts from human lymphocytes prod

16 in dye-primer sequencing as a substitute for ddA.

17 more than 500,000-fold for the series ddC > ddA (ddI) > 2',3'-didehydro-2',3'-dideoxythymidine (d4T)

18 V > AZT > PMPA approximately equal to d4T >> ddA (ddI) >> ddC.

19 reatment with chelerythrine but not by NMLA, ddA, TMB-8, or Quin-2.

20 On the other hand, SQ22,536, but not ddAd, inhibited the effects of cAMP analogs 8-Br-cAMP an

21 48 times less efficiently incorporated than ddA.

22 abine (ddC) > didanosine (ddI metabolized to ddA) > stavudine (d4T) >> lamivudine (3TC) > tenofovir (

23 deoxy compounds, ddC and ddI (metabolized to ddA), may be a combination of high rates of incorporatio

24 ghtfold resistance to AZT-triphosphate (TP), ddA-TP, and ddC-TP, indicating an MDNR phenotype.

25 as a 2',3'-dideoxyadenosine-5'-triphosphate (ddA) surrogate.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。